Display options
Cite
Kotzsch M, Kirchner T, Soelch S, et al. Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis. Am J Cancer Res. 2017;7(9):1959-1970
Kotzsch, M., Kirchner, T., Soelch, S., Schäfer, S., Friedrich, K., Baretton, G., Magdolen, V., & Luther, T. (2017). Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis. American journal of cancer research, 7(9), 1959-1970.
Kotzsch, Matthias, et al. "Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis." American journal of cancer research vol. 7,9 (2017): 1959-1970.
Kotzsch M, Kirchner T, Soelch S, Schäfer S, Friedrich K, Baretton G, Magdolen V, Luther T. Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis. Am J Cancer Res. 2017 Sep 01;7(9):1959-1970. eCollection 2017. PMID: 28979817; PMCID: PMC5622229.
Copy Download .nbib Format: NLM
Share it on

Am J Cancer Res. 2017 Sep 01;7(9):1959-1970. eCollection 2017.

Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.

American journal of cancer research

Matthias Kotzsch, Thomas Kirchner, Susanne Soelch, Sonja Schäfer, Katrin Friedrich, Gustavo Baretton, Viktor Magdolen, Thomas Luther

Affiliations

  1. Medizinisches Labor OstsachsenD-02526 Bautzen, Germany.
  2. Institut für Pathologie, Technische Universität DresdenD-01307 Dresden, Germany.
  3. Klinische Forschergruppe, Klinik für Frauenheilkunde und Geburtshilfe, Technische Universität MünchenD-81675 München, Germany.

PMID: 28979817 PMCID: PMC5622229

Abstract

Dysregulated expression of rab31, a member of the large Rab protein family of the Ras superfamily of small GTPases, has been observed in several types of cancer, including breast cancer. Rab31, depending on its expression level, may regulate the switch between an invasive versus proliferative phenotype of breast cancer cells

Keywords: CA15-3; Rab31; antigen levels; breast cancer; mucin-1; prognosis; tumour tissue extracts

Conflict of interest statement

None.

References

  1. Br J Cancer. 1991 Sep;64(3):501-7 - PubMed
  2. Anticancer Res. 2013 Jan;33(1):293-9 - PubMed
  3. Cell Adh Migr. 2013 Mar-Apr;7(2):187-98 - PubMed
  4. Biochem Biophys Res Commun. 2007 Sep 28;361(3):751-7 - PubMed
  5. PLoS One. 2012;7(7):e39432 - PubMed
  6. BMC Genomics. 2005 Mar 11;6:37 - PubMed
  7. Mol Cancer. 2012 Aug 24;11:62 - PubMed
  8. Nat Med. 1996 May;2(5):491-2 - PubMed
  9. Mod Pathol. 2005 Oct;18(10):1295-304 - PubMed
  10. J Breast Cancer. 2013 Jun;16(2):152-8 - PubMed
  11. Oncogene. 2013 Feb 28;32(9):1073-81 - PubMed
  12. Semin Cell Dev Biol. 2011 Feb;22(1):57-68 - PubMed
  13. Int J Cancer. 1989 Jun 15;43(6):1072-6 - PubMed
  14. Mol Cancer Res. 2013 Jul;11(7):714-23 - PubMed
  15. Dev Cell. 2007 Oct;13(4):496-510 - PubMed
  16. Hum Pathol. 1995 Apr;26(4):432-9 - PubMed
  17. Cancer Res. 1994 May 15;54(10):2527-30 - PubMed
  18. Lancet Oncol. 2010 Feb;11(2):174-83 - PubMed
  19. Am J Pathol. 2002 Oct;161(4):1223-33 - PubMed
  20. Breast Cancer Res Treat. 2008 Sep;111(2):229-40 - PubMed
  21. Eur J Pediatr. 2008 Jul;167(7):723-9 - PubMed
  22. J Pathol. 2011 Aug;224(4):529-39 - PubMed
  23. Histopathology. 1991 Nov;19(5):403-10 - PubMed
  24. Pathologe. 1987 May;8(3):138-40 - PubMed
  25. Cytometry. 1993;14(5):482-5 - PubMed
  26. J Neurosci Res. 2001 Dec 15;66(6):1149-60 - PubMed
  27. Small GTPases. 2015 ;6(3):135-44 - PubMed
  28. Curr Opin Genet Dev. 2013 Feb;23(1):35-43 - PubMed
  29. Nat Rev Mol Cell Biol. 2009 Aug;10 (8):513-25 - PubMed
  30. Trends Cell Biol. 2010 Jun;20(6):329-36 - PubMed
  31. Mol Neurobiol. 2016 Sep;53(7):4431-7 - PubMed
  32. Cancer Sci. 2015 Mar;106(3):307-14 - PubMed
  33. Medicine (Baltimore). 2015 Dec;94(50):e2286 - PubMed
  34. BMC Biol. 2012 Aug 08;10 :71 - PubMed
  35. Drug Discov Today. 2017 Aug;22(8):1139-1147 - PubMed
  36. Clin Cancer Res. 2001 Apr;7(4):909-17 - PubMed
  37. Cancer Res. 2005 Apr 1;65(7):2516-9 - PubMed
  38. Oncogene. 2003 Mar 6;22(9):1324-32 - PubMed
  39. Cancer. 2001 Jun 1;91(11):1973-82 - PubMed
  40. J Biol Chem. 2006 Sep 1;281(35):25678-88 - PubMed
  41. Biochim Biophys Acta. 2009 Apr;1795(2):110-6 - PubMed
  42. Br J Cancer. 2013 Mar 5;108(4):873-80 - PubMed
  43. Clin Chim Acta. 2010 Dec 14;411(23-24):1869-74 - PubMed
  44. Biochem Soc Trans. 2012 Dec 1;40(6):1389-93 - PubMed
  45. Nat Rev Cancer. 2009 Dec;9(12):874-85 - PubMed
  46. Eur J Cancer. 2005 Nov;41(17):2760-8 - PubMed
  47. Mol Cancer. 2010 Dec 09;9:312 - PubMed
  48. Mol Cancer. 2006 Nov 05;5:57 - PubMed
  49. Biochim Biophys Acta. 2011 Apr;1815(2):224-40 - PubMed
  50. Cancer Res. 2005 Mar 15;65(6):2157-61 - PubMed
  51. J Biomed Sci. 2016 Oct 6;23 (1):70 - PubMed

Publication Types